189 related articles for article (PubMed ID: 20122924)
1. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.
Loomis K; Smith B; Feng Y; Garg H; Yavlovich A; Campbell-Massa R; Dimitrov DS; Blumenthal R; Xiao X; Puri A
Exp Mol Pathol; 2010 Apr; 88(2):238-49. PubMed ID: 20122924
[TBL] [Abstract][Full Text] [Related]
2. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
Kawa S; Onda M; Ho M; Kreitman RJ; Bera TK; Pastan I
MAbs; 2011; 3(5):479-86. PubMed ID: 22048691
[TBL] [Abstract][Full Text] [Related]
3. Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem.
Sun M; Wang J; Lu Q; Xia G; Zhang Y; Song L; Fang Y
Drug Des Devel Ther; 2015; 9():5123-33. PubMed ID: 26379425
[TBL] [Abstract][Full Text] [Related]
4. Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies.
Kim B; Shin J; Kiziltepe T; Bilgicer B
Nanoscale; 2020 Jun; 12(21):11672-11683. PubMed ID: 32436925
[TBL] [Abstract][Full Text] [Related]
5. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Chen WC; Sigal DS; Saven A; Paulson JC
Leuk Lymphoma; 2012 Feb; 53(2):208-10. PubMed ID: 21756025
[TBL] [Abstract][Full Text] [Related]
6. Generation of anti-idiotype scFv for pharmacokinetic measurement in lymphoma patients treated with chimera anti-CD22 antibody SM03.
Zhao Q; Wong PF; Lee SS; Leung SO; Cheung WT; Wang JZ
PLoS One; 2014; 9(5):e96697. PubMed ID: 24816427
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
Mussai F; Campana D; Bhojwani D; Stetler-Stevenson M; Steinberg SM; Wayne AS; Pastan I
Br J Haematol; 2010 Aug; 150(3):352-8. PubMed ID: 20528877
[TBL] [Abstract][Full Text] [Related]
8. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells.
Collins BE; Blixt O; Han S; Duong B; Li H; Nathan JK; Bovin N; Paulson JC
J Immunol; 2006 Sep; 177(5):2994-3003. PubMed ID: 16920935
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
10. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
[TBL] [Abstract][Full Text] [Related]
11. Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.
Saeed M; van Brakel M; Zalba S; Schooten E; Rens JA; Koning GA; Debets R; Ten Hagen TL
Int J Nanomedicine; 2016; 11():955-75. PubMed ID: 27022262
[TBL] [Abstract][Full Text] [Related]
12. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes).
Smith B; Lyakhov I; Loomis K; Needle D; Baxa U; Yavlovich A; Capala J; Blumenthal R; Puri A
J Control Release; 2011 Jul; 153(2):187-94. PubMed ID: 21501640
[TBL] [Abstract][Full Text] [Related]
13. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
Front Immunol; 2018; 9():820. PubMed ID: 29725338
[TBL] [Abstract][Full Text] [Related]
14. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo.
Haas KM; Sen S; Sanford IG; Miller AS; Poe JC; Tedder TF
J Immunol; 2006 Sep; 177(5):3063-73. PubMed ID: 16920943
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of fully human anti-CD22 monoclonal antibodies.
Xiao X; Ho M; Zhu Z; Pastan I; Dimitrov DS
MAbs; 2009; 1(3):297-303. PubMed ID: 20065646
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
17. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Wei H; Xiang L; Wayne AS; Chertov O; FitzGerald DJ; Bera TK; Pastan I
Proc Natl Acad Sci U S A; 2012 May; 109(18):6898-903. PubMed ID: 22509046
[TBL] [Abstract][Full Text] [Related]
18. Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
Velasco-Hernandez T; Zanetti SR; Roca-Ho H; Gutierrez-Aguera F; Petazzi P; Sánchez-Martínez D; Molina O; Baroni ML; Fuster JL; Ballerini P; Bueno C; Fernandez-Fuentes N; Engel P; Menendez P
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788237
[TBL] [Abstract][Full Text] [Related]
19. Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model.
Wöhner M; Born S; Nitschke L
Eur J Immunol; 2012 Nov; 42(11):3009-18. PubMed ID: 22965838
[TBL] [Abstract][Full Text] [Related]
20. High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris.
Zarei N; Vaziri B; Shokrgozar MA; Mahdian R; Fazel R; Khalaj V
Appl Microbiol Biotechnol; 2014 Dec; 98(24):10023-39. PubMed ID: 25239038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
